Drug intelligence / Profile preview

AP-cannabinoids

Development stage: Phase 3
Lead developer: Indaptus Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

AP-Cannabinoids is a gastro-retentive, controlled-release oral formulation of cannabinoids developed by Intec Pharma using its proprietary Accordion Pill (AP) technology. The platform consists of a multi-layered, biodegradable film containing the active pharmaceutical ingredients—typically cannabidiol (CBD) and tetrahydrocannabinol (THC)—which is folded into a standard-size capsule. Upon reaching the stomach, the pill unfolds and is retained in the gastric cavity for several hours, allowing for continuous release and improved bioavailability of the cannabinoids, which otherwise have poor and erratic absorption profiles. The program was primarily targeted at treating chronic pain conditions such as low back pain and fibromyalgia.

Other names: Accordion Pill Cannabinoids

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on AP-cannabinoids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP-cannabinoids.